Inhaled Interferon-Beta for Respiratory Virus Prophylaxis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods struggle to effectively prevent self-replication infection of respiratory viruses, particularly coronaviruses, due to their high contagiousness and similar initial symptoms, making early differentiation difficult and leading to rapid pandemics.

Innovation Solution

Administering interferon-beta directly to respiratory cells through inhalation as an active ingredient to restrain self-replication of respiratory viruses, including coronaviruses, by binding to the interferon beta receptor.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If interferon-beta is administered to prevent respiratory virus infection, then viral replication is restrained and infection is prevented, but the complexity of the pharmaceutical composition and administration protocol increases

Engineering Contradiction:

Improveinfection prevention efficacyVSAvoidpharmaceutical composition complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The pharmaceutical composition is segmented into multiple functional components: interferon-beta as the active antiviral ingredient, carriers for delivery, and optional adjuvants to enhance efficacy. This segmentation allows each component to perform its specific function while maintaining overall composition manageability and effectiveness.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Carrier molecules serve as intermediaries to deliver interferon-beta to target respiratory cells. These carriers facilitate the transport and localization of the active ingredient, enabling effective drug delivery while simplifying the administration process and reducing the need for complex delivery systems.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If interferon-beta is administered early to restrain viral self-replication, then pandemic spread is reduced, but the difficulty of early virus differentiation and targeted administration increases

Engineering Contradiction:

Improvevirus spread control efficiencyVSAvoidearly virus differentiation difficulty

Core Design Contradiction:

ProductivityVSDifficulty of detecting and measuring

Solution Approach 1:

The pharmaceutical composition is designed for preliminary administration before clinical symptoms fully develop. By providing interferon-beta prophylactically or at the earliest signs of exposure, the treatment prevents viral replication before it can establish widespread infection, eliminating the need for complex virus differentiation in the early stages.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The pharmaceutical composition has universal applicability across multiple respiratory virus types including coronaviruses, influenza viruses, and other respiratory pathogens. This multi-functionality allows the same composition to be used for various viruses, simplifying early intervention strategies without requiring virus-specific differentiation.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Ease of operation

If interferon-beta is used as the sole active ingredient, then the treatment is simple and cost-effective, but the efficacy may be insufficient for severe infections

Engineering Contradiction:

Improvetreatment simplicityVSAvoidtreatment efficacy

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The pharmaceutical composition uses interferon-beta as the core active ingredient and combines it with carriers and optional adjuvants to create a composite formulation. This composite structure maintains the simplicity of using interferon-beta as the primary therapeutic agent while enhancing overall efficacy through the synergistic effects of additional components, making it suitable for both mild and severe infections.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Interferon-beta effectively reduces viral replication and lung damage, offering both pre-exposure and post-exposure prophylaxis, with superior efficacy compared to Remdesivir, and demonstrates significant infection restraint across various respiratory viruses.

Implementation Method 1

administering interferon-beta as an active ingredient to respiratory cells through breathing in the manner of direct administration to cells infected with or potentially infected with a respiratory virus

Methodology Applied

Scientific EffectReceptor binding:

Data Source

PatentUS20250281576A1Prophylactic administration method against respiratory virus, comprising administering interferon-beta to potential respiratory virus-infected subject

Publication Date: 2025.09.11 ABION INC

AI summary

The present invention relates to a prophylactic administration method against respiratory viruses, comprising administering interferon-beta to a potential respiratory virus-infected subject, and more specifically, to a method for restraining self-replication infection of respiratory viruses in a subject exposed to potential respiratory virus infection by administering interferon-beta as an active ingredient to respiratory cells through breathing in the manner of direct administration to cells infected with or potentially infected with a respiratory virus.